COVID-19 Variant
Expert Insights on COVID-19 Prophylaxis in Patients With Multiple Sclerosis and Related Disorders
This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.
Q&A: What to know about the SARS-CoV-2 ‘FLiRT’ variants
Together, a group of viruses nicknamed “FLiRT” have emerged to become the most common SARS-CoV-2 variants in the country.
Benefits of routine COVID-19 testing depend on circulating variant virulence
The cost-effectiveness of routine COVID-19 testing among nursing home staff depended on the virulence of variants circulating during the time of testing, researchers found.
Updated COVID-19 vaccines effective against variants, new data show
The updated COVID-19 vaccines were approximately 54% effective against symptomatic SARS-CoV-2 infection and offered protection against JN.1 and XBB viral lineages, according to early estimates published Thursday by the CDC.
Untangling the Drug–Drug Interaction Web in COVID-19 Outpatient Management – A GameOn! Challenge
This activity is supported by an educational grant from Pfizer Inc.
COVID-19 mRNA booster provides additional protection, most beneficial for older adults
BOSTON — Boosting with mRNA-1273 provided additional COVID-19 protection during the delta and omicron waves, and especially among older adults, according to data from the phase 3 coronavirus efficacy (COVE) trial presented at IDWeek.
COVID-19 in Immunocompromised Patients: Is Prevention Better Than Cure? – A Podcast Series
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
CDC recommends updated COVID-19 vaccines
The CDC on Tuesday recommended the updated monovalent COVID-19 vaccines for people aged older than 6 months.
FDA approves updated COVID-19 vaccines
The FDA on Monday approved and authorized updated COVID-19 vaccines from Moderna and Pfizer-BioNTech that target omicron XBB subvariants of SARS-CoV-2.
Fourth dose of bivalent COVID-19 vaccine more protective than monovalent booster in study
A fourth dose of a bivalent COVID-19 vaccine provided added protection for previously infected and SARS-CoV-2 naïve patients compared with a fourth dose of a monovalent vaccine, researchers in Singapore found.